Humacyte (HUMA) FY 2025 Conference May 20, 2025 12:30 PM ET Speaker0 EVs for vascular repair and replacement. In December, FDA approved SIMVAS as a vascular conduit for treating extremity vascular trauma, and the product was launched in February of this year. The company is also evaluating SymVest in other diseases such as peripheral artery disease and also has a second product that is, designed for use in, CABG surgery. To learn about Symvest's commercial potential and the development strategy going forwar ...